Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer launches Revatio in the UK

Pfizer launches Revatio in the UK

7th March 2006

Pfizer has begun marketing its pulmonary arterial hypertension (PAH) drug Revatio in the UK.

The treatment, which uses the same active ingredient as impotence drug Viagra, was approved by European regulators in November under an indication for the life-threatening condition, following approval by the US Food and Drug Administration in June.

PAH has been diagnosed in 4,000 people in the UK, according to the Press Association. The condition causes high bloody pressure in the artery between the heart and the lungs. Symptoms include breathlessness, tiredness and angina.

Trials of Revatio found that the drug improved the six-minute walk distance made by PAH sufferers ? a major benchmark used in trials involving PAH treatments.

Competition to treat PAH sufferers is hotting up, with dominant treatment Tracleer facing competition from many of the world’s largest medical corporations.

GSK and Myogen announced this week that they will co-operate to market and fund two PAH drugs. After the announcement Actelion, which produces Tracleer, saw it share price dip by three per cent in early morning trading, Reuters reported.

Analysts said that GSK’s greater ability to market outside of the US may help successfully push Myogen developmental drug ambrisentan.

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.